Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.54 |
| ▸ | SHBG | P04278 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28290185 | 0.88 | HTT (0.70) | HTTSMN1; SMN2ALDH1A1KDM4EPDE4B | |
| SCHEMBL3377350 | 0.86 | GAA (0.67) | HTTALDH1A1KDM4EMAPTNPSR1 | |
| SCHEMBL16884088 | 0.86 | HTT (0.76) | HTTSMN1; SMN2ALDH1A1KDM4EPDE4B | |
| SCHEMBL4150936 | 0.85 | GAA (0.69) | HTTALDH1A1KDM4EMAPTNPSR1 | |
| SCHEMBL9996727 | 0.84 | KDM4E (0.64) | HTTALDH1A1KDM4EMAPTNPSR1 | |
| SCHEMBL10899727 | 0.83 | GAA (0.71) | HTTSMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL29788564 | 0.82 | HTT (0.66) | HTTSMN1; SMN2ALDH1A1PDE4B | |
| SCHEMBL521236 | 0.82 | HTT (0.66) | HTTSMN1; SMN2ALDH1A1PDE4B | |
| SCHEMBL14514871 | 0.82 | HTT (0.66) | HTTSMN1; SMN2ALDH1A1MAPTNPSR1 | |
| SCHEMBL1014420 | 0.81 | HTT (0.60) | HTTSMN1; SMN2ALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-9555022-B2 | Substituted triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-20130156756-A1 | Substituted Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130156756-A1 | Substituted Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130156756-A1 | Substituted Triazolopyridines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| EP-2582699-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | Bayer Intellectual Property GmbH (DE) | 2013-04-24 | — | — | EP | disclosed |
| WO-2012160029-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012160029-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2011157688-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157688-A1 | SUBSTITUTED TRIAZOLOPYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-22 | — | — | WO | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | EXONHIT THERAPEUTICS SA (FR) | 2009-05-07 | — | — | US | disclosed |
| EP-1910334-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | Exonhit Therapeutics SA (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007034329-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS | EXONHIT THERAPEUTICS SA (FR) | 2007-03-29 | — | — | WO | disclosed |
| EP-1746092-A1 | Compounds and methods for treatment of amyloid-B-peptide related disorders | Exonhit Therapeutics SA (FR) | 2007-01-24 | — | — | EP | disclosed |
| EP-1746092-A1 | Compounds and methods for treatment of amyloid-B-peptide related disorders | Exonhit Therapeutics SA (FR) | 2007-01-24 | — | — | EP | disclosed |
| WO-2003047572-A1 | USE OF 1-PHENYL-OXAZOLIDINE-2-ONE COMPOUNDS AS PROTEASE M INHIBITORS | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156756-A1 | Substituted Triazolopyridines | CCND2, CCND1, QDPR | HTT 1703/4885SMN1; SMN2 188/4885ALDH1A1 847/4885 |
| US-20090118282-A1 | Compounds and methods for treatment of amyloid-beta-peptide related disorders | APP, BACE1, IAPP | HTT 33/4885SMN1; SMN2 1581/4885ALDH1A1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.